ELIQUIS® (apixaban)
Quick Reference Dosing Guide

ELIQUIS for the treatment of NVAF / DVT / PE

dosing quick reference dosing quick reference
aristotle result aristotle result

This Dosing Card may be read in its electronic form (PDF) or it may be printed and read.

If the Dosing Card is printed, please ensure that:

  • It is printed in its entirety. Please do not attempt to print and use individual pages in isolation, as it has been designed to be printed in entirety
  • Its content is not edited or altered in any way
  • It is printed in colour
  • It is printed on A4 size paper
  • The pages are placed in the correct order as per the page numbering

ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1


  • BD = Twice Daily   DOAC = Direct-acting Oral Anticoagulant   INR = International Normalised Ratio   SmPC = Summary of Product Characteristics   UFH = Unfractionated Heparin


  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Alexander JH et al. JAMA Cardiol 2016; 1: 673-681
  3. Agnelli G et al. N Engl J Med 2013; 369: 799-808
  4. Steffel J et al. Eur Heart J 2018; 39: 1330–1393.

Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie

Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com